Treats iron deficiency anemia (IDA). ANDA 212340, held by Sandoz. Iron Sucrose.
As of Nov 16, 2026, ANDA 212340 (Iron Sucrose), held by Sandoz, was first approved by FDA on Aug 8, 2025, with 1 approved supplement and 0 published complete response letters.
Iron sucrose injection is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 8, 2025 | Original application | Approved |
| Iron SucroseEQ 50MG IRON/2.5ML (EQ 20MG IRON/ML) · injectable;intravenous | Iron Sucrose | Rx |
| Iron SucroseEQ 100MG IRON/5ML (EQ 20MG IRON/ML) · injectable;intravenous | Iron Sucrose | Rx |
| Iron SucroseEQ 200MG IRON/10ML (EQ 20MG IRON/ML) · injectable;intravenous | Iron Sucrose | Rx |
| Sep 22, 2025 | Supplement 1Manufacturing | Approved | None posted |
| Aug 8, 2025 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters